Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas (original) (raw)

Nature Medicine volume 3, pages 231–234 (1997)Cite this article

Abstract

The cell-cycle inhibitor p27 is a potential tumor suppressor, but its gene has never been found inactivated in human tumors1–4. Because cell-cycle regulation of p27 cellular abundance occurs at the post-transcriptional level5–7, we analyzed p27 protein expression and degradation in human colorectal carcinomas. Proteasome-mediated degradation activity of p27 was compared with its protein levels in a subset of tumor samples. We found that carcinomas with low or absent p27 protein displayed enhanced proteolytic activity specific for p27, suggesting that low p27 expression can result from increased proteasome-mediated degradation rather than altered gene expression. Patients whose tumors expressed p27 had a median survival of 151 months, whereas patients who lacked p27 (10%) had a median survival of 69 months. By multivariate analysis, p27 was found to be an independent prognostic marker. Lack of p27 was associated with poor prognosis (2.9 risk ratio for death; P = 0.003). The absence of p27 protein expression is thus a powerful negative prognostic marker in colorectal carcinomas, particularly in stage II tumors, and thereby may help in the selection of patients who will benefit from adjuvant therapy. These data suggest that aggressive tumors may result from the selection of a clone or clones that lack p27 due to increased proteasome-mediated degradation.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Kawamat, A.N. et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 55, 2266–2269 (1995).
    Google Scholar
  2. Ponce-Castañeda, V. et al. p27Kip1: Chromosomal mapping to 12p12–12p13.1 and absence of mutations in human tumors. Cancer Res. 55, 1211–1214 (1995).
    PubMed Google Scholar
  3. Pietenpol, J. et al. Assignment of the human p27Kip1 gene to 12pl 3 and its analysis in leukemias. Cancer Res. 55, 1206–1210 (1995).
    CAS PubMed Google Scholar
  4. Stegmaier, K. et al. Mutational analysis of the candidate tumor suppressor genes Tel and Kip1 in childhood acute lymphoblastic leukemia. Cancer Res. 56, 1413–1417 (1996).
    CAS PubMed Google Scholar
  5. Pagano, M. et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269, 682–685 (1995).
    Article CAS PubMed Google Scholar
  6. Hengst, L. & Reed, S. Translation control of p27Kip1 accumulation during the Cell cycle. Science 271, 1861–1864 (1996).
    Article CAS PubMed Google Scholar
  7. Yan, J. et al. Association of p27 mRNA with ribosomes regulates abundance of the cyclin-dependent inhibitor p27Kip1 as Cells withdraw from the Cell cycle. J. Biol. Chem. (in the press).
  8. Maki, C., Hulbregtse, J. & Howley, P. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56, 2649–2654 (1996).
    CAS PubMed Google Scholar
  9. Committee on Cancer. Manual for Staging of Cancer, 4th edn. (eds. Beahrs, O.H., Henson, D.E., Mutter, R.V.P. & Kennedy, B.J., (Lippincott, New York, 1992).
  10. Sahin, A. et al. Assessment of Ki-67-derived tumor proliferative activity in colorectal adenocarcinomas. Mod. Pathol. 7, 17–22 (1994).
    CAS PubMed Google Scholar
  11. Risio, M., Coverlizza, S., Ferrari, A., Candelaresi, G. & Rossini, S. Immunohistochemical study of epithelial Cell proliferation in hyperplastic polyps, adenomas, and adenocarcinomas of the large bowel. Gastroenterology 94, 899–906 (1988).
    Article CAS PubMed Google Scholar
  12. Brown, J.P. & Pagano, M. The mechanism of p53 degradation. Biochim. Biophys. Acta (in the press).
  13. Loda, M. et al. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am. J. Pathol. 149, 1553–1564 (1996).
    CAS PubMed PubMed Central Google Scholar
  14. Kaplan, E.L. & Meier, P. Nonparametric estimation from incomplete observations. J. Am. Statist. Assoc. 53, 457–481 (1958).
    Article Google Scholar
  15. Gehan, E.A. A generalized Wilcoxon test for comparing arbitrarily singly-censored data. Biometrika 52, 203–223 (1965).
    Article CAS PubMed Google Scholar
  16. Mantel, N. & Haenszel, W. Statistical aspect of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22, 719–749 (1959).
    CAS PubMed Google Scholar
  17. Cox, D. Regression models and life tables (with discussion). J. R. Statist. Soc. B. 34, 187–220 (1972).
    Google Scholar
  18. Jonckheere, A.R. A distribution-free K-sample test against ordered alternatives. Biometrika 41, 133–145 (1954).
    Article Google Scholar
  19. Kruskal, W.H. & Wallis, W.A. Use of ranks in one-criterion variance analysis. J. Am. Statist. Assoc. 47, 583–621 (1952).
    Article Google Scholar
  20. Pagano, M., Pepperkok, R., Verde, F., Ansorge, W. & Draetta, G. Cyclin A is required at two points in the human Cell cycle. EMBO J. 11, 761–771 (1992).
    Article Google Scholar
  21. Palombella, V., Rando, O., Goldberg, A. & Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78, 773–785 (1994).
    Article CAS PubMed Google Scholar

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Beth Israel Deaconess Medical Center, West Campus, Harvard Medical School, 1 Deaconess Road, Boston, Massachusetts, 02215, USA
    Massimo Loda, Barry Cukor & Michelangelo Fiorentinc
  2. Mitotix Inc., One Kendall Square, Building 600, Cambridge, Massachusetts, 02139, USA
    Sun W. Tam & Michele Pagano
  3. Boston Biostatistics Research Foundation, Inc., 615 Concord Street, Framingham, Massachusetts, 01702, USA
    Philip Lavin
  4. European Institute of Oncology, Via Ripamonti, 435, Milan, 20141, Italy
    Glulio F. Draetta
  5. Department of Surgery, Beth Israel Deaconess Medical Center, West Campus, Harvard Medical School, 1 Deaconess Road, Boston, Massachusetts, 02215, USA
    J. Milburn Jessup
  6. Department of Pathology, MSB 548, New York University Medical Center, 550 First Avenue, New York, New York, 10016, USA
    Michele Pagano

Authors

  1. Massimo Loda
    You can also search for this author inPubMed Google Scholar
  2. Barry Cukor
    You can also search for this author inPubMed Google Scholar
  3. Sun W. Tam
    You can also search for this author inPubMed Google Scholar
  4. Philip Lavin
    You can also search for this author inPubMed Google Scholar
  5. Michelangelo Fiorentinc
    You can also search for this author inPubMed Google Scholar
  6. Glulio F. Draetta
    You can also search for this author inPubMed Google Scholar
  7. J. Milburn Jessup
    You can also search for this author inPubMed Google Scholar
  8. Michele Pagano
    You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Loda, M., Cukor, B., Tam, S. et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.Nat Med 3, 231–234 (1997). https://doi.org/10.1038/nm0297-231

Download citation

This article is cited by